Histogen Inc.

Equities

HSTO

US43358Y2028

Biotechnology & Medical Research

Delayed OTC Markets Other stock markets 19:12:44 28/05/2024 BST			5-day change	1st Jan Change
0.17 ^USD	0.00%		0.00%	-44.75%

04-19	Subchapter V Trustee Appointed Under Chapter 11 for Histogen Inc.	CI
04-18	Histogen Inc. Filed for Bankruptcy	CI

Histogen Inc. Announces Executive Changes

November 08, 2021 at 09:05 pm

Histogen Inc. announced that Steven J. Mento, Ph.D., a current member of the Histogen Board of Directors, has been appointed Chief Executive Officer effective November 8, 2021. Richard Pascoe has stepped down as Chief Executive Officer effective November 8, 2021, to pursue different opportunities. A search has commenced to identify a permanent CEO.

Latest news about Histogen Inc.

Subchapter V Trustee Appointed Under Chapter 11 for Histogen Inc.	04-19	CI
Histogen Inc. Filed for Bankruptcy	04-18	CI
Histogen Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	11-09	CI
Histogen Inc.(OTCPK:HSTO) dropped from NASDAQ Composite Index	04/10/23	CI
Histogen Inc. and Allergan Mutually Elect to Terminate the Amended and Restated License Agreement	03/10/23	CI
Histogen Inc.(NasdaqCM:HSTO) dropped from S&P TMI Index	22/09/23	CI
Wall Street Set to Open Wednesday Trading Higher as Investors Await Fed Decision on Interest Rates	20/09/23	MT
Top Premarket Gainers	20/09/23	MT
Histogen Says Board Approved Complete Liquidation, Dissolution	18/09/23	MT
Histogen Inc. Announces Executive Changes	18/09/23	CI
Histogen Inc. Announces Board and Executive Changes	18/09/23	CI
Histogen Announces Update on Potential Strategic Alternatives	18/09/23	CI
Histogen Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	10/08/23	CI
North American Morning Briefing : Fed Hawks Hit Stocks	06/07/23	DJ
Histogen to Weigh Strategic Alternatives; Shares Jump After Hours	05/07/23	MT
Histogen to Explore Strategic Alternatives	04/07/23	CI
Histogen Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	11/05/23	CI
North American Morning Briefing : Stock Futures Edge Up Ahead of Looming Catalysts	04/04/23	DJ
Histogen Announces Exclusive Intellectual Property License Agreement with Johns Hopkins University	03/04/23	CI
Histogen Gets US Patent Offering Broad Coverage for Anti-Inflammatory Caspase Inhibitors; Shares Rise Pre-Bell Friday	17/03/23	MT
Top Premarket Gainers	17/03/23	MT
Histogen Inc. Announces Executive Changes	14/03/23	CI
Histogen Inc. Appoints Steven J. Mento, as Chief Executive Officer	14/03/23	CI
Histogen Inc. Reports Earnings Results for the Full Year Ended December 31, 2022	09/03/23	CI
Histogen Inc. Auditor Raises 'Going Concern' Doubt	08/03/23	CI

Chart Histogen Inc.

Duration

Period

More charts

Company Profile

Histogen Inc. is a clinical-stage therapeutics company. The Company is focused on developing clinical and preclinical small molecule pan-caspase and caspase selective inhibitors that protect the bodyâs natural process to restore immune function. Its product candidates include emricasan, CTS-2090 and CTS-2096. It develops emricasan for acute bacterial skin and skin structure infections (ABSSSI) as well evaluating its use for other infectious diseases. Its pipeline also includes novel preclinical product candidates including CTS-2090 and CTS-2096, which are selective small molecule inhibitors of caspase-1 designed for the treatment of certain inflammatory diseases. Emricasan is an orally available pan-caspase inhibitor designed to reduce the activities of human caspases, which are enzymes that mediate inflammation and apoptosis. CTS-2090 and CTS-2096 are selective caspase-1 inhibitors targeting inflammasome activation and to treat a variety of inflammation mediated diseases.

Sector

Biotechnology & Medical Research

More about the company

Income Statement Evolution

More financial data

Quarterly revenue - Rate of surprise

Company calendar

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
HISTOGEN INC.	-44.75%	726K
VERTEX PHARMACEUTICALS INCORPORATED	+9.88%	118B
REGENERON PHARMACEUTICALS, INC.	+10.19%	106B
BIONTECH SE	-11.86%	23.4B
ARGENX SE	-1.69%	22.1B
GENMAB A/S	-10.23%	18.34B
WUXI APPTEC CO., LTD.	-41.92%	16.59B
BEIGENE, LTD.	-15.55%	15.97B
NEUROCRINE BIOSCIENCES, INC.	+6.44%	14.03B
SAREPTA THERAPEUTICS, INC.	+15.28%	11.67B

Bio Therapeutic Drugs